Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DTN-CKD: Dotinurad for hyperuricemia in patients with kidney dysfunction (G1–G4)
jRCTs061210079Completed
- Sponsor
- Mochida Pharmaceutical Co., Ltd.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of dotinurad in hyperuricemia and chronic kidney disease (CKD), sponsored by Mochida Pharmaceutical Co., Ltd. Primary endpoint: Percent change in serum uric acid levels at 24 weeks in G1/G2 vs G3/G4. Started Mar 2022; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCTs061210079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061210079.